Connor, Clark & Lunn Investment Management Ltd. Kiniksa Pharmaceuticals, Ltd. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 09, 2024	BUY	$17.63 - $21.74 $42,576 - $52,502	2,415 Added 0.93%	261,698 $5.16 Million
Q4 2023 Feb 09, 2024	BUY	$14.37 - $19.07 $33,783 - $44,833	2,351 Added 0.92%	259,283 $4.55 Million
Q3 2023 Nov 13, 2023	BUY	$13.62 - $20.2 $1.31 Million - $1.95 Million	96,288 Added 59.94%	256,932 $4.46 Million
Q2 2023 Aug 10, 2023	BUY	$10.44 - $16.48 $1.26 Million - $1.98 Million	120,278 Added 297.97%	160,644 $2.26 Million
Q1 2023 May 09, 2023	BUY	$10.7 - $15.79 $192,674 - $284,330	18,007 Added 80.54%	40,366 $434,000
Q4 2022 Feb 10, 2023	BUY	$11.42 - $17.05 $255,339 - $381,220	22,359 New	22,359 $334,000

Others Institutions Holding KNSA

# of Institutions

Shares Held

1.95M

Call Options Held

Put Options Held

Pictet Asset Management Sa Geneva 73, V8

1.52M
Shares

$33.1 Million
0.03% of portfolio
Spearhead Capital Advisors, LLC Wellington, FL

203K
Shares

$4.42 Million
2.82% of portfolio
Harbor Capital Advisors, Inc.

97.5K
Shares

$2.13 Million
0.11% of portfolio
Putnam Investments LLC Boston, MA

39.5K
Shares

$860,794
0.0% of portfolio
Birchview Capital, LP Burlington, VT

30K
Shares

$654,000
0.69% of portfolio

View Full List

About Kiniksa Pharmaceuticals, Ltd.

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $751M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

More about KNSA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account